Cyx Solid Tumor 505
Clinical Services
Cyx Solid Tumor 505 enables rapid and actionable genomic insights for all patients with advanced cancer. FDA-cleared and CE-IVD-marked comprehensive tumor profiling affords every patient access to personalized treatment options.
Product Features
- Trustworthy: FDA-cleared detection chemistry and CE-IVD-marked with overall clinical pass rate of 92.9%
- Fast: Results generated in less than a week via streamlined automation workflow and automated bioinformatics
- Actionable: 505 solid tumor-related genes, including all FDA-approved and professional guideline-supported biomarkers, with easy-to-interpret results
- Automated: On-site automation improves efficiency, consistency, and reduces human errors
Detection Chemistry Development & Validation
- Pan solid tumor: 35 solid tumor types across9 organ systems
- Robust: >7,300 analytical samples tested
- Rigorous: 15,000 hours of sequencing time
- Accurate: 13 orthogonal methods used for comparison, including PCR, IHC, FISH, RNA and DNA-based NGS approaches
Assay Specifications
| Sample requirements | FFPE Tissue, Slides, or Blocks |
| Tumor purity minimum | 20% |
| Regions analyzed | Coding regions of 505 genes; non-coding regions for translocations |
| Mutation Identification | MSI, TMB, Translocations , Indels, SNVs, & Amplifications |
| Read length | 2.23 Mb total |
| Average total coverage | 2,300x |
Sample Pathology Report
